Radiation Oncology
Consensus Recommendations | Radiation therapy in oligometastatic prostate cancer.
19 Oct, 2022 | 14:24h | UTCRelated: AUA/ASTRO Guideline: Clinically localized prostate cancer.
Consensus on re-irradiation: definition, reporting, and clinical decision making.
7 Oct, 2022 | 14:16h | UTC
Podcast | Oncologic Emergencies: from cord compression to tumor lysis syndrome.
6 Oct, 2022 | 13:41h | UTC#358 Oncologic Emergencies with Dr. Aditi Singh – The Curbsiders
RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.
19 Sep, 2022 | 12:31h | UTCIntensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
My first Tweetorial ? 2 year toxicity results of PACE B published here. Big thanks to the ???? and??collaborators and the 874 men with prostate cancer who made this trial possible https://t.co/mERz2ox8TM
— Alison Tree ??? (@alison_tree) September 14, 2022
RCT | Busulfan plus Cyclophosphamide is noninferior to total body irradiation plus Cyclophosphamide for adults Acute B Lymphoblastic Leukemia.
11 Sep, 2022 | 22:24h | UTC
Guideline | Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer.
1 Sep, 2022 | 11:53h | UTC
Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.
31 Aug, 2022 | 11:45h | UTCDe-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV
— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022
Systematic Review | Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
26 Aug, 2022 | 13:11h | UTC
RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.
25 Aug, 2022 | 12:13h | UTCEffect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)
Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA
The contemporary management of cancers of the sinonasal tract in adults.
16 Aug, 2022 | 13:39h | UTC
RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.
9 Aug, 2022 | 12:46h | UTCRadiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
RCT | Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus.
9 Aug, 2022 | 12:24h | UTCCommentary: Esophagus-Sparing Radiation Fails QOL Test in Lung Cancer— Esophageal-specific quality of life no better, but treatment reduced symptomatic esophagitis – MedPage Today (free registration required)
Commentary on Twitter
PROACTIVE was a phase 3 RCT of 90 pts with incurable lung cancer treated with esophageal sparing IMRT vs. standard palliative RT. ES-IMRT did not improve FACT-E ECS quality of life scores at 2wks but reduced grade≥2 esophagitis (24% vs. 2%). https://t.co/ExIp22WBPe #RadOnc #LCSM pic.twitter.com/lX8lD4Duja
— JAMA Oncology (@JAMAOnc) February 24, 2022
RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.
8 Aug, 2022 | 11:36h | UTCPartial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
ASTRO Guideline | Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma.
29 Jul, 2022 | 12:33h | UTC
Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.
29 Jul, 2022 | 12:23h | UTC
Commentary on Twitter
In this cohort study of patients with localized prostate cancer, radiotherapy was associated with a small increase in the risk of developing a second primary cancer. https://t.co/YsrNo3FKwM
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.
19 Jul, 2022 | 12:58h | UTCDeintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentaries:
Commentary on Twitter
Less is more? ? 2-cycle cisplatin concurrent chemoradiotherapy is not inferior to 3-cycles based on 3-yr PFS in treating locoregionally advanced nasopharyngeal ca w/preRX EBV DNA levels < 4000.QOL & toxicity improved w/ less chemo https://t.co/XovHi2P06W pic.twitter.com/JJqiC8wnWW
— Journal of Clinical Oncology (@JCO_ASCO) January 25, 2022
Phase 2 RCT | Efficacy of preoperative mFOLFIRINOX vs. mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas.
15 Jul, 2022 | 12:29h | UTCEfficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer – JAMA (free for a limited period)
Commentary on Twitter
Ph 2 trial of 126 pts w/borderline resectable pancreatic ductal adenoCa shows 18 mo OS after neoadjuvant mFOLFIRINOX of 66.7%, favorable vs. historical data; 18m OS if mFOLFORINOX then hypofract RT is 47.3%, if chemo then pancreatectomy is 87.5%. https://t.co/wOMNrTOAzm
— JAMA Oncology (@JAMAOnc) July 14, 2022
Female erectile tissues and sexual dysfunction after pelvic radiotherapy: a scoping review.
13 Jul, 2022 | 11:23h | UTC
Phase II RCT | Proton craniospinal irradiation vs. photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.
13 Jul, 2022 | 11:09h | UTCRandomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis – Journal of Clinical Oncology (link to abstract – $ for full-text)
Network M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
Long-term results of RCT: Radiotherapy to the prostate for men with metastatic prostate cancer.
10 Jun, 2022 | 11:10h | UTC
ESTRO-ACROP guideline on surface guided radiation therapy.
7 Jun, 2022 | 10:53h | UTCESTRO-ACROP guideline on surface guided radiation therapy – Radiotherapy & Oncology
Commentary on Twitter
Now available! First European guideline on Surface Guided Radiation Therapy (SGRT): ESTRO-ACROP guideline on surface guided radiation therapy?https://t.co/YC8Vk8g4h1 @OncologyAdvance @RadiotherapyOn1 #Radonc #Radiotherapy #Oncology
— ESTRO (@ESTRO_RT) June 2, 2022
ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.
7 Jun, 2022 | 10:52h | UTC
M-A: Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer.
3 Jun, 2022 | 10:46h | UTC
Phase 2 RCT: Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy.
2 Jun, 2022 | 10:34h | UTCEfficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Visual Abstract: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy